Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Acelyrin rejected a bid by Concentra and Atara cut staff.

Migliaccio & Rathod is investigating a recent recall of the Accolade Pacemaker produced by Boston Scientific. If you have one of these pacemakers we would like to speak with you. Please complete the ...

The funding can support investment in as many as 60 new life sciences companies, said Sofinnova chairman Antoine Papiernik.

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency ...

The meeting, which helps the FDA give guidance to vaccine makers on which flu strains to target, is the second to be ...